A side-by-side comparison of two Healthcare investors: HSG (Power Score 85/100) and Perceptive Advisors (Power Score 82/100), both ranked among the most active firms tracked in this category.
| HSG | Perceptive Advisors | |
|---|---|---|
| Power Score™ | 85/100 | 82/100 |
| Assets Managed | Over US$61B (assets for institutional investors as of 30 June 2026, per hsgcap.com/about-us) | Approximately $11B (across its strategies as of 30 June 2026, per the firm's own About page; the firm's Form ADV Item 5.F figure could not be read) |
| Founded | 2005 | 1999 |
| Headquarters | Hong Kong, China | New York, NY |
| Sectors | Technology, Healthcare, Consumer | Biotech, Life Sciences, Medical Devices, Diagnostics, Digital Health, Healthcare IT |
HSG describes itself on its own About Us page as a venture capital and private equity firm, formerly known as Sequoia China, investing globally across technology, healthcare and consumer sectors. Its Chinese-language site describes the same three areas as 科技, 医疗 and 消费, and lists its investment stages as seed-stage, growth-stage, buyout, new-infrastructure and public-market investing (种子期投资, 成长期投资, 并购投资, 新基建投资, 公开市场投资). The firm states it has backed more than 1,800 companies, that over 190 of them have gone public and that over 140 have become unicorns. It states offices in Hong Kong, Shanghai, Beijing, Shenzhen, London, Tokyo and Singapore.
View full HSG profile →Perceptive Advisors is a life sciences investment manager registered with the SEC as an investment adviser (CRD 154703, SEC registration effective 4 October 2010). It says it runs four strategies. The Perceptive Life Sciences Fund invests globally in public and private companies developing biotechnology products, drugs, medical devices and diagnostics, with the majority of investments in publicly traded small and mid cap companies, and participates in growth rounds, crossover rounds, IPOs and public follow-ons. Credit Opportunities, launched with its first closed-end fund in 2014, lends to healthcare companies across biopharma, medical devices, diagnostics, digital health, women's health, life sciences research and healthcare IT, and states a range of $20M to $300M per investment and approximately $3.5B of capital raised for private credit. Capital Solutions provides structured capital to later-stage and commercial-stage life sciences companies. The venture strategy, run through the Perceptive Xontogeny Venture Funds, invests primarily at seed and Series A in biotechnology, medtech, healthtech, digital health and healthcare tools and services, states investments of $10M to $50M when leading or co-leading a Series A, states over $700M across its venture funds, and says its people take board seats. The firm describes its team as scientists, technologists, molecular biologists, MDs and PhDs.
View full Perceptive Advisors profile →